Lesion Dosimetry With Iodine-124 in Metastatic Thyroid Carcinoma

Inclusion Criteria

• •Adults with thyroid carcinoma confirmed by pathology.
• •Adult thyroid carcinoma patients who have undergone total thyroidectomy
• •Adult thyroid carcinoma patients have metastatic disease or suspicion for metastatic disease, or are under a protocol intended to explore re-induction therapy for 131I uptake, and are about to undergo Thyrogen-assisted dosimetry, unless Thyrogen-assisted dosimetry is not required per standard of care.
• •The patient and physician are planning to administer 131I for therapy if persistent radioiodine-avid metastases are present.
• •All subjects must have measurable disease, documented within the previous six months by ultrasonography (US), MRI, FDG PET/CT, or CT scanning.